Entering text into the input field will update the search result below

Sarepta's Eteplirsen demonstrates stability on pulmonary function

Feb. 05, 2014 9:11 AM ETSarepta Therapeutics, Inc. (SRPT) StockBy: Yigal Grayeff, SA News Editor4 Comments
  • Sarepta Therapeutics' (NASDAQ:SRPT +3.4%) Eteplirsen treatment for Duchenne muscular dystrophy demonstrates stability on pulmonary function tests through 120 Weeks in a Phase IIb Study of twelve boys aged 7-13 years.
  • In the age group tested, pulmonary function would be expected to drop over the analysis period, says Sarepta's Edward Kaye. The results "provide early evidence towards achieving a key treatment goal, the delay or avoidance of pulmonary ventilation assistance in DMD patients."
  • The results add to data showing a general stabilization of walking ability in Eteplirsen-treated patients. (PR)

Recommended For You

About SRPT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SRPT--
Sarepta Therapeutics, Inc.